New York (EFE)
Those elevated enzymes can often cause liver damage.
However, the pharmaceutical giant said that no patients experienced “liver-related symptoms or side effects, there was no evidence of liver failure and none required treatment.”
New York-based Pfizer said it will instead focus on its other oral obesity drug, danuglipron, which is in a clinical trial.
One study indicated that body weight was reduced after patients with type 2 diabetes took high-dose versions of danuglipron twice daily for 16 weeks, according to results published by Pfizer, and that the “most common adverse events were nausea , vomiting and diarrhea.
“The company expects to finalize plans for the danuglipron late-stage program by the end of 2023,” the company statement noted.
A joint battle against diabetes and obesity
This year the popularity of this type of diabetes medication for weight loss has grown.
Danish drugmaker Novo Nordisk’s experimental high-dose obesity pill helped obese or overweight adults lose around 15% of their body weight, according to the results of a new clinical trial presented Sunday.
Meanwhile, researchers this weekend presented data indicating that the next iteration of Ozempic and Wegovy – hitherto injectable diabetes drugs known for their ability to induce weight loss – could be produced in pill form.